U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT07493538) titled 'MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases' on March 20.
Brief Summary: This is a Phase II study following subjects proceeding with Treosulfan (36g/m2) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion, with post-transplant cyclophosphamide (PTCy) at 40mg/kg, tacrolimus and MMF for GVHD prophylaxis.
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
AML
MDS
Acute Leukemia
Acute Myeloid Leukemia
M...